Applied dna sciences inc (APDN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10
Cash flows from operating activities:
Net loss

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-11,072

-10,795

-12,078

-12,855

-12,416

-13,172

-13,211

-12,175

-10,256

-8,560

-6,978

-11,881

-13,490

-13,738

-14,603

-13,066

-14,679

-14,896

-15,273

-17,686

-15,735

-15,029

-13,445

-7,150

-9,800

-10,526

-11,580

-10,515

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

299

330

390

441

477

525

547

572

610

628

633

635

642

650

706

694

647

599

490

470

463

446

442

426

375

290

206

118

159

236

313

391

379

373

367

0

0

0

Stock-based compensation

804

844

1,129

2,083

2,167

1,615

1,356

879

1,207

2,030

3,257

3,156

3,148

3,099

2,038

1,935

2,392

2,420

4,022

3,846

3,235

3,266

2,033

1,900

1,957

1,865

1,517

1,724

2,768

2,370

1,953

0

0

0

-

-

0

0

Fair value of vested options issued to officers, directors and employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on conversion of promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

980

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Common stock issued for consulting services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

78

0

0

0

-

-

-

-

337

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of vested options issued to officers, directors and employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Amortization of debt issuance costs

-

25

23

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

85

213

484

749

858

0

0

0

Amortization of debt discount attributable to convertible debentures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

541

1,088

1,651

2,453

2,096

0

0

0

Common stock issued in settlement of interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

102

509

512

124

36

0

0

0

Provision for bad debts

16

16

7

0

0

0

-

-

-

-

423

378

115

112

116

119

54

42

34

24

6

7

19

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

249

-324

-638

-1,180

-1,214

-1,529

-1,081

-2,660

-2,477

-2,688

-3,084

1,191

1,326

1,764

2,597

3,189

3,926

4,357

4,635

1,594

560

372

181

-45

291

479

453

214

84

129

88

264

224

169

145

0

0

0

Inventories

-225

-142

-78

14

20

-88

-105

-81

-59

-9

28

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets and deposits

100

-4

-23

-51

22

88

268

490

393

408

167

318

379

302

297

-88

-44

-11

78

26

51

33

-32

33

104

89

109

48

1

2

16

17

-16

-28

-70

0

0

0

Accounts payable and accrued liabilities

85

-324

667

526

521

665

426

92

-132

-526

-610

-82

-209

-56

-253

726

1,080

1,174

1,241

159

-115

39

527

193

644

535

517

1,244

836

436

239

-937

-550

-163

-199

0

0

0

Deferred revenue

-533

-920

-727

-995

500

1,532

1,504

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-1,469

741

1,838

2,202

2,455

643

-177

-466

-301

-143

-188

199

434

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-8,211

-8,079

-6,861

-7,594

-7,439

-5,858

-6,917

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Purchase of property and equipment

11

15

67

64

126

269

266

303

255

151

145

189

638

663

672

724

282

372

351

241

317

165

229

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-9,372

-9,244

-9,896

-9,189

-8,217

-7,330

-6,965

-7,468

-8,221

-8,802

-8,512

-8,444

-8,243

-8,196

-7,870

-6,689

-6,006

-4,889

-3,960

-4,529

-4,114

-4,103

-3,761

0

0

0

Purchase of intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

112

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-48

-15

-67

-64

-126

-269

-266

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from Promissory notes (related parties $550,000)

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of secured convertible promissory notes

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-713

-756

-779

-2,311

-2,065

-2,173

-2,138

-479

-352

-165

-229

-632

-1,300

-1,315

-1,220

-894

-145

-162

-162

0

0

0

-

-

-

0

Net proceeds from sale of common stock and warrants

10,623

10,912

2,463

2,463

2,479

2,301

4,233

5,737

6,004

6,197

6,105

4,600

4,333

4,333

7,853

7,853

19,011

19,011

19,114

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from (payments of) related party advances

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-50

0

0

0

Net proceeds from sale of common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,900

0

0

0

-

-

-

-

-

-

-

-

Purchase and cancelation of previously issued warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,895

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

4,319

4,319

7,843

7,857

19,085

19,015

15,023

0

0

0

-

-

-

-

14,726

0

0

0

-

-

-

-

6,580

0

0

0

Net cash provided by financing activities

15,381

13,619

5,828

5,651

5,397

4,501

5,883

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

112

-311

-1,937

-1,519

-4,683

-5,765

-5,681

-2,832

-3,643

8,801

9,511

5,919

8,704

-1,004

-1,327

-4,967

193

-2,417

3,214

5,635

575

3,549

-951

-2,022

1,243

733

1,467

2,729

0

0

0

Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Cash paid during period for income taxes

0

0

0

0

0

0

0

0

0

0

0

0

-4

0

0

0

0

0

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Non-cash investing and financing activities:
Impact of adoption of new accounting pronouncements included in accumulated deficit

0

0

493

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid in kind (related party of $35,550 for the six month period ended March 31, 2019)

113

162

126

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued upon cashless exercise of options and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of deferred offering costs to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs incurred, and included in accounts payable

83

171

99

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment acquired, and included in accounts payable

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend-warrant repricing

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock and warrants issued upon conversion of promissory notes payable and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,687

4,005

4,043

1,226

373

0

0

0

Property and equipment acquired, and included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

237

-138

1

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets acquired, and included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of options to settle accrued liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued for cashless exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs reclassified to additional paid in capital

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-